Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Dyfarnu Contract

This Is a Restricted Process. The Supply of Construction Services for the Cell Gene Therapy Manufact

  • Cyhoeddwyd gyntaf: 11 Mehefin 2018
  • Wedi'i addasu ddiwethaf: 11 Mehefin 2018

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
Cyhoeddwyd gan:
Cell & Gene Therapy Catapult
ID Awudurdod:
AA58950
Dyddiad cyhoeddi:
11 Mehefin 2018
Dyddiad Cau:
-
Math o hysbysiad:
Dyfarnu Contract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

The Client is looking for contractors who:

— are financially sound,

— have suitable technical skills in respect of design, programming fast-track projects, coordination and integration of design and construction-related activities,

— have, together with their proposed supply chain sub-contractors and suppliers, specific expertise, experience and skills in delivering projects of a similar nature to the CGT requirement involving the design, commissioning and successful handover.

2 / 4

— possess the necessary skills to obtain and implement any required statutory approvals,

— possess an exceptional health and safety record — our requirement is reflected in the allocated weightings for the questions relating to health and safety within this SQ,

— have managed the design and construction process to deliver similar projects to at least an “Very Good” BREEAM standard,

— are familiar with, and have experience in working to BIM Level 2,

— can provide evidence of their expertise and a proven commitment to delivery within agreed programmes, costs, quality and, most importantly, focused delivery to meet client objectives.

The concept design is currently being developed but the requirement is likely to involve the following as progressed but is likely to include:

— the fit out of approximately 3 000 m2. In addition, there will be an interstitial plant ceiling above the module ceiling plate,

— flexible configuration Grade C Clean room space suitable for Advanced Therapy Medicinal Product manufacture, with the ability to deliver multiple parallel processes for Autologous product manufacturing, and the flexibility to convert the clean spaces to manufacture either Allogeneic products at up to 1 000 L scale, gene modified products or regenerative organs. The clean rooms will also have the flexibility for conversion between Grade C and Grade D classifications,

— potential extension to the existing warehouse and QC facility,

— completion of external works and access road (held over from Phase 1),

— works completed in an occupied building,

— it must achieve the requisite licences for GMP manufacturing from the MHRA and be capable of meeting all regulatory requirements in significant markets worldwide, including US FDA cGMPs,

— it will be based on the Manufacturing module principle developed at the Cell and Gene Therapy Catapult with additional flexible support space.

Testun llawn y rhybydd

Hysbysiad dyfarnu contract

Canlyniadau'r weithdrefn gaffael

Adran I: Awdurdod contractio

I.1) Enw a chyfeiriad

Cell Therapy Catapult Ltd

12th Floor Tower Wing, Guuy's Hospital, Great Maze Pond

London

SE1 9RT

UK

Person cyswllt: Angela Porter

E-bost: ojeu@ct.catapult.org.uk

NUTS: UK

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: https://ct.catapult.org.uk/

I.4) Y math o awdurdod contractio

Arall: private company limited by guarantee

I.5) Prif weithgaredd

Arall: Cell and Gene Therapy Research

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

This Is a Restricted Process. The Supply of Construction Services for the Cell Gene Therapy Manufacturing Centre Phase 2

Cyfeirnod: CON-0104

II.1.2) Prif god CPV

71500000

 

II.1.3) Y math o gontract

Gwaith

II.1.4) Disgrifiad byr

With Phase 1 due to complete mid 2017, there is a business need to increase the number of modules within the facility from the 6nr completed as part of Phase 1 to 12nr (Phase 2).

Expressions of interest are sought from suitably qualified contractors responding to this SQ PQQ, who will need to demonstrate experience in successfully delivering the fit out of complex, GMP biologics manufacturing projects of the scale and to the programme required for this Project. Cell and Gene Therapy intends to appoint a combined project management and design team to work with CGT to deliver the proposed Phase 2 of the Project.

The Client is looking for contractors who:

— are financially sound,

— have suitable technical skills in respect of design, programming fast-track projects, coordination and integration of design and construction-related activities,

— have, together with their proposed supply chain sub-contractors and suppliers, specific expertise, experience and skills in delivering projects of a similar.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.1.7) Cyfanswm gwerth y caffaeliad

Cynnig isaf: 9 000 000.00 GBP / Y cynnig uchaf: 11 000 000.00 GBP

II.2) Disgrifiad

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

Stevenage Hertfordshire.

II.2.4) Disgrifiad o’r caffaeliad

The Client is looking for contractors who:

— are financially sound,

— have suitable technical skills in respect of design, programming fast-track projects, coordination and integration of design and construction-related activities,

— have, together with their proposed supply chain sub-contractors and suppliers, specific expertise, experience and skills in delivering projects of a similar nature to the CGT requirement involving the design, commissioning and successful handover.

2 / 4

— possess the necessary skills to obtain and implement any required statutory approvals,

— possess an exceptional health and safety record — our requirement is reflected in the allocated weightings for the questions relating to health and safety within this SQ,

— have managed the design and construction process to deliver similar projects to at least an “Very Good” BREEAM standard,

— are familiar with, and have experience in working to BIM Level 2,

— can provide evidence of their expertise and a proven commitment to delivery within agreed programmes, costs, quality and, most importantly, focused delivery to meet client objectives.

The concept design is currently being developed but the requirement is likely to involve the following as progressed but is likely to include:

— the fit out of approximately 3 000 m2. In addition, there will be an interstitial plant ceiling above the module ceiling plate,

— flexible configuration Grade C Clean room space suitable for Advanced Therapy Medicinal Product manufacture, with the ability to deliver multiple parallel processes for Autologous product manufacturing, and the flexibility to convert the clean spaces to manufacture either Allogeneic products at up to 1 000 L scale, gene modified products or regenerative organs. The clean rooms will also have the flexibility for conversion between Grade C and Grade D classifications,

— potential extension to the existing warehouse and QC facility,

— completion of external works and access road (held over from Phase 1),

— works completed in an occupied building,

— it must achieve the requisite licences for GMP manufacturing from the MHRA and be capable of meeting all regulatory requirements in significant markets worldwide, including US FDA cGMPs,

— it will be based on the Manufacturing module principle developed at the Cell and Gene Therapy Catapult with additional flexible support space.

II.2.5) Meini prawf dyfarnu

Maes prawf ansawdd: The requested information has been supplied and also to carry out the “Pass / Fail” tests to be applied. The evaluation of the Technical Requirements were be based on as / Pwysoliad: 70 %

Price / Pwysoliad:  30 %

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn gyfyngedig

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Na

IV.2) Gwybodaeth weinyddol

IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon

Rhif yr hysbysiad yn OJ S:

2018/S 006-010281

IV.2.9) Gwybodaeth am ddod â chais am gystadleuaeth i ben ar ffurf hysbysiad gwybodaeth ymlaen llaw

Ni fydd yr awdurdod contractio yn dyfarnu contractau pellach yn seiliedig ar yr hysbysiad gwybodaeth ymlaen llaw uchod

Section V: Dyfarnu contract

Rhif Contract: CON-0104

Teitl: He Supply of Construction Services for the Cell Gene Therapy Manufacturing Centre Phase 2 Stevenage

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

24/04/2018

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 4

Nifer y tendrau a ddaeth i law gan BBaChau: 0

Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau yr UE: 0

Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau nad ydynt yn aelodau o'r UE: 0

Nifer y tendrau a ddaeth i law drwy ddulliau electronig: 4

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Merit Holdings Ltd

3 Silverton Court, Northumberland Business Park

Cramlington

NE23 7RY

UK

NUTS: UK

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 11 000 000.00 GBP

Cynnig isaf: 9 000 000.00 GBP / Y cynnig uchaf: 11 000 000.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section VI: Gwybodaeth ategol

VI.3) Gwybodaeth ychwanegol

In addition to current text also to be clear: This contract was awarded to Merit Holdings Ltd as they were theonly bidder that agreed to Cell & Gene Therapy Catapult Terms & Conditions. As part of the restricted processthese were not negotiable.

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

Cell and Gene Therapy Catapult

London

UK

VI.5) Dyddiad anfon yr hysbysiad hwn

03/06/2018

Codio

Categorïau nwyddau

ID Teitl Prif gategori
71500000 Gwasanaethau goruchwylio safleoedd adeiladu Gwasanaethau pensaernïol, adeiladu, peirianneg ac archwilio

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
ojeu@ct.catapult.org.uk
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.